BioSpace News Archive

Pyramid Biosciences, Inc. today announced the initial close of its Series B financing.

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), today announced that the IND application submitted by its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to initiate a Phase 1/1b clinical trial of Corvus’ small molecule ITK inhibitor CPI-818 for the treatment of relapsed/refractory T-cell lymphomas (TCL) in China.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today that the company will release financial results for the third quarter 2021, after the market close on Wednesday, November 3, 2021.

Precigen, Inc. today announced that the Company will host a virtual event on Thursday, November 4, 2021 at 11:00 AM ET

Supernus Pharmaceuticals, Inc. today announced that the Company expects to report financial and business results for the third quarter of 2021 after the market closes on Wednesday, November 3, 2021.

Innovent Biologics, Inc. and NeoCura Bio-Medical Technology Co., Ltd. jointly announced that they have entered into a strategic collaboration agreement to carry out a clinical study in China on the combination therapy of sintilimab from Innovent and individualized neoantigen vaccine NEO_PLIN2101 from NeoCura.

Phathom Pharmaceuticals, Inc., a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced the withdrawal of the previously announced, proposed primary and secondary public offering.

Acceleron Announces Third Quarter 2021 REBLOZYL ® Net Sales

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), today announced that it has successfully synthesized a novel psilocin analogue with improved pharmaceutical properties to further expand its library of patent-pending tryptamines.

InflaRx N.V. announces positive data from the third cohort of patients in the Phase IIa open-label study with vilobelimab in Pyoderma Gangraenosum (PG).